Are billions of people around the globe foolish for wearing facemasks to protect against the flu? A portion of the mainstream media seems to believe so. They report that wearing a protective facemask is ineffective because the virus particle is so small that it passes right through. Read more »
January 24, 2014- Interviewed by Steven E. Greer, MD
Erik Dutson, MD, weight loss surgeon at UCLA, explains why his medical center does not implant the Lap-Band, and how the “sleeve” bypass is the main procedure of choice now for weight loss surgery.
August 11, 2014- Interviewed by Steven E. Greer, MD
Above, in Part 1 of our interview with the CEO of Dexcom, Terry Gregg, we review the business model and products. Mr. Gregg explains how continuous glucose monitoring is safer than finger-stock monitoring.
In Part 2 of the interview, we discuss the bionic pancreas programs underway in academia, and why the Dexcom CGM is the chosen device in most of them.
In Part 3 of the interview, we discuss the financial status of Dexcom. We also go over in more detail the pipeline, and how Apple Computer will be a major partner for Dexcom.
October 21, 2014- By Steven E. Greer
Another huge credit card data security hack was in the news today. Read more »
July 9, 2014- Interviewed by Steven E. Greer, MD
Senator Angus King from Maine has proposed a a bill that would make the pricing of medical devices more transparent. Currently, hospitals are required to sign confidentiality agreements, and the market is entirely in the dark. If such a law were passed, it would turn the medical device industry on its head.
October 19, 2014- Interviewed by Steven E. Greer, MD
Alessio Fasano, MD of Harvard discusses his 10-year-long study in children testing whether the delayed introduction of gluten into the diet reduced the eventual incidence of celiac disease. Dr. Fasano is most responsible for raising awareness of gluten intolerance after his 2003 NEJM and Archives of Internal Medicine papers were published.
October 19, 2014- Interviewed by Steven E. Greer, MD
Did you know that one out of three Americans think that they are “gluten intolerant”. Of those 100 Million people, only 13 Million really have a medical problem caused by gluten.
Alessio Fasano, MD, director of the Center for Celiac Research and Treatment at MassGeneral Hospital for Children, is the man who started all of the gluten hype back in 2003 with a paper in the Archives of Internal Medicine. Hoping to reduce some of the current “gluten hysteria,” he has written a book explaining what gluten is, who can and can’t eat it, and why. We interviewed him.
In the general news, British Parliament voted to recognize the Palestinian state. The nurse in Spain and two in the U.S. infected with Ebola recovered, as the CDC was profoundly criticized for poor handling of the scare. The stock markets reacted by selling off 10%. In media, HBO and CBA announced a de-bundling plan that would sell their products on the Internet, meaning a quicker end to cable TV.
In healthcare business news, earning began with JNJ posting strong drug revenue. The Abbvie (ABBV) and Shire inversion merger was cancelled. Steris (STE) acquired Britain’s Synergy Health for $1.9 Billion for the inversion tax benefits. Lastly, Mankind (MNKD) reaped a $150 Million milestone on Afrezza, sending the stock up 16%.
On the data front, Regeneron’s (REGN) Eylea outperformed Roche’s Avastin and Lucentis in diabetics. Alnylam (ALNY) posted 6-month data on Patisiran to treat rare Familial Amyloidotic Polyneuropathy.Lastly, NewLink Genetics (NLNK) tested an Ebola vaccine.
The mainstream media has correctly reported on the numerous missteps made by the Dallas Presbyterian Hospital when the first Ebola case, Thomas Eric Duncan, presented to them, and then the subsequent “protocol” mistakes that caused two nurses to become infected with Ebola. However, the press still characterizes the decision to discharge the patient, even when he arrived with a fever and had a history of travel from Africa, as a “misdiagnosis”. Read more »
In the general news, global Ebola fears dominated the news, from Africa to Spain to Dallas, where a patient died, then a nurse caring for him also became infected.
In healthcare business news, Becton Dickinson (BDX) acquired CareFusion (CFN) for $12 B. Endo International acquired Auxilium (AUX) as part of a tax-reduction inversion deal. Also, Actavis (ACT) made a move to acquire Allergan (AGN) as the Valeant (VRX) attempt stalls.
From the FDA, a third FDA panel. once again, recommend approval of the Boston Scientific (BSX) left atrial occlusion device called Watchman. The Bard (BCR) Lutonix drug coated balloon to treat peripheral vascular disease was approved. Salix’s (SLXP) foam delivery of drug Uceris (budesonide) to treat ulcerative colitis was approved. Eisai’s drug Akynzeo for nausea was approved. Regeneron (REGN) received a label expansion for Eylea to treat retinal vein occlusion macular edema, and Gilead’s (GILD) combo pill Harvoni (ledipasvir and sofosbuvir) was approved.
In other regulatory news, Senator Bernie Sanders and Rep. Elijah Cummings launched an investigation into price gouging by generic drug companies. Also, The White House and the CDC prepared plans to treat Ebola patients in remote hospitals away from urban areas as the military put boots on the ground in Africa to help stem the source of the outbreak.